New insider activity at Supernus Pharmaceuticals ( (SUPN) ) has taken place on August 27, 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In recent transactions involving Supernus Pharmaceuticals stock, Frank Mottola, the Senior Vice President of Quality, GMP, Ops, and IT, sold 14,000 shares, amounting to a total of $623,140. Additionally, Jack Khattar, the President and CEO, sold 1,000 shares, generating $45,000 from the sale.
Recent Updates on SUPN stock
In the last 24 hours, Supernus Pharmaceuticals has experienced significant developments following its Q2 earnings call. The company reported robust growth in its core products, Qelbree and GOCOVRI, with Qelbree prescriptions growing by 23% and net sales up by 31%. The launch of ONAPGO, a new treatment for Parkinson’s disease, exceeded expectations, contributing to the company’s positive outlook. Additionally, the strategic acquisition of Sage Therapeutics is expected to enhance revenue and cash flow growth, positioning Supernus for sustained success. Despite these positive developments, the company faced challenges with a decline in operating earnings due to increased sales and marketing expenses. Analyst Cantor Fitzgerald upgraded Supernus to Overweight from Neutral, citing a more positive outlook on Qelbree, which is believed to be redefining the treatment landscape for ADHD. This upgrade was influenced by a survey indicating a growing preference for non-stimulant prescriptions, with Qelbree expected to play a significant role in this trend.
Spark’s Take on SUPN Stock
According to Spark, TipRanks’ AI Analyst, SUPN is a Outperform.
Supernus Pharmaceuticals demonstrates strong financial health and technical momentum, supported by strategic acquisitions. However, high valuation and patent challenges pose risks. The company’s robust cash flow and operational efficiency are key strengths, but attention to revenue growth and cost management is crucial for sustaining long-term performance.
To see Spark’s full report on SUPN stock, click here.
More about Supernus Pharmaceuticals
YTD Price Performance: 21.66%
Average Trading Volume: 804,849
Technical Sentiment Signal: Buy
Current Market Cap: $2.49B